XML 31 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration and Other Agreements, Provention (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2018
USD ($)
performance_obligation
$ / shares
shares
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaboration and Other Agreements [Line Items]                        
Revenues   $ 25,192 $ 18,741 $ 10,593 $ 9,662 $ 15,794 $ 20,798 $ 18,834 $ 4,695 $ 64,188 $ 60,121 $ 157,742
Deferred revenue   10,700       21,721       10,700 21,721  
Deferred revenue included in long-term liabilities   9,153       19,001       9,153 19,001  
Provention Bio, Inc. (Provention)                        
Collaboration and Other Agreements [Line Items]                        
Number of performance obligations | performance_obligation 2                      
Transaction price $ 6,100                      
Stock warrants (in shares) | shares 2,432,688                      
Green Cross                        
Collaboration and Other Agreements [Line Items]                        
Deferred revenue           $ 1,900         $ 1,900  
Deferred revenue included in long-term liabilities   $ 20,100               $ 20,100    
Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention)                        
Collaboration and Other Agreements [Line Items]                        
Consideration received common stock warrant exercise price (in usd per share) | $ / shares $ 2.50                      
Potential development and regulatory milestone payments $ 65,000                      
Potential commercial milestone payments $ 225,000                      
Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention)                        
Collaboration and Other Agreements [Line Items]                        
Consideration received common stock warrant exercise price (in usd per share) | $ / shares $ 2.50                      
Potential development and regulatory milestone payments $ 170,000                      
Potential commercial milestone payments 225,000                      
Potential milestone payment to third parties for intellectual property under agreement 1,300                      
Revenues From License Agreements | Provention Bio, Inc. (Provention)                        
Collaboration and Other Agreements [Line Items]                        
Revenues $ 6,100